We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Paper-Based Portable Diagnostic Platform Accurately Detects Mosquito-Borne Diseases Under Field Conditions

By LabMedica International staff writers
Posted on 09 Mar 2022

Field trails conducted in Latin America have shown that a paper-based portable diagnostic platform could accurately detect patients with mosquito-borne diseases with sensitivities equivalent to laboratory PCR tests. More...

In low-resource settings, resilience to infectious disease outbreaks can be hindered by limited access to diagnostic tests. In response to this limitation, investigators at the University of Toronto (Canada) and the biotech company LSK Technologies (Toronto, Canada) developed a portable diagnostic platform that was a combination of a cell-free, paper-based test and a field-ready companion device that allowed data to be collected using image-based color analysis. Called “PLUM” (Portable, Low-cost, User-friendly, Multimode), the conveniently-sized reader presented results from up to 384 samples and displayed them in a single image capture.

In the initial studies, the platform was optimized for detection of first Zika and then chikungunya viruses with reagents that could be freeze-dried, allowing for distribution without refrigeration

Using RNA extracted from the serum of patient samples collected in Brazil, the investigators found that the combined PLUM reader and paper-based Zika sensor provided analytical sensitivity and specificity for the Zika virus equivalent to RT–qPCR (quantitative real-time PCR) with a diagnostic accuracy of 98.5%. The investigators then demonstrated that by simply changing the molecular components that confer specificity to the assay, they could detect the chikungunya virus with 98.5% accuracy.

“We see emerging diagnostics, like the paper-based tests we have developed, as having tremendous near-term potential to augment existing PCR capacity, improve equity in access to health care, and aid in the responses to public health crises,” said senior author Dr. Keith Pardee, assistant professor of pharmaceutical sciences at the University of Toronto.

A sticking point delaying the field use of the PLUM system is that the extraction of RNA from patient samples requires liquid handling by skilled technicians. “With performance on patient samples now validated, we are tackling these next challenges, like sample preparation, so that the platform and PCR-like diagnostic capacity can be distributed more broadly into the communities where they are needed,” said Dr. Pardee.

The Zika virus field test was described in the March 7, 2022, online edition of the journal Nature Biomedical Engineering.

Related Links:
University of Toronto 
LSK Technologies 


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.